ADCs currently approved for use in lymphomas include brentuximab vedotin (Bv, targeting CD30), polatuzumab vedotin (targeting CD79B), and loncastuximab tesirine (targeting CD19). This evidence concerns the gene TNFRSF8 and lymphoma.